The “living with COVID” strategy being pursued by many countries relies heavily on two key pillars. First, that vaccines continue to protect most people from severe disease. And second, that where they don’t, people will receive antiviral treatments. But are the antivirals currently available sufficiently effective, accessible and durable?
Research advances in the realm of antiviral therapies since the pandemic began have been considerable. At the same time, no medicine is perfect. The concern is that if not deployed properly, the effectiveness and longevity of antiviral treatments may be compromised.
